Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Gallbladder Neoplasms 1

Interventions

Gemcitabine 39Cisplatin 24Oxaliplatin 21Capecitabine 20Fluorouracil 11Leucovorin 9Irinotecan 9130-nm albumin-bound paclitaxel 8durvalumab 6Taxes 5Radiotherapy 5Platinum 4Immunohistochemistry 4Erlotinib Hydrochloride 4Docetaxel 4Carboplatin 4Bevacizumab 4Albumin-Bound Paclitaxel 41,2-diaminocyclohexaneplatinum II citrate 4trifluridine tipiracil drug combination 3Trastuzumab 3Sorafenib 3Observation 3Epirubicin 3Drug Therapy 3tremelimumab 2toripalimab 2regorafenib 2pembrolizumab 2anlotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gallbladder Neoplasms × Commerce × Clear all
NCT04183712 2024-10-16

Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
102 enrolled
Gastrointestinal

Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡